In vitro and in vivo accumulation of the anticancer Ru complexes [RuII(cym)(HQ)Cl] and [RuII(cym)(PCA)Cl]Cl
- PMID: 37962611
- DOI: 10.1007/s00775-023-02026-w
In vitro and in vivo accumulation of the anticancer Ru complexes [RuII(cym)(HQ)Cl] and [RuII(cym)(PCA)Cl]Cl
Abstract
The cellular accumulation and the underlying mechanisms for the two ruthenium-based anticancer complexes [RuII(cym)(HQ)Cl] 1 (cym = η6-p-cymene, HQ = 8-hydroxyquinoline) and [RuII(cym)(PCA)Cl]Cl 2 (PCA = N-fluorophenyl-2-pyridinecarbothioamide) were investigated in HCT116 human colorectal carcinoma cells. The results showed that the cellular accumulation of both complexes increased over time and with higher concentrations, and that 2 accumulates in greater quantities in cells than 1. Inhibition studies of selected cellular accumulation mechanisms indicated that both 1 and 2 may be transported into the cells by both passive diffusion and active transporters, similar to cisplatin. Efflux experiments indicated that 1 and 2 are subjected to efflux through a mechanism that does not involve p-glycoprotein, as addition of verapamil did not make any difference. Exploring the influence of the Cu transporter by addition of CuCl2 resulted in a higher accumulation of 1 and 2 whilst the amount of Pt detected was slightly reduced when cells were treated with cisplatin. Complexes 1 and 2 were further explored in zebrafish where accumulation and distribution were determined with ICP-MS and LA-ICP-MS. The results correlated with the in vitro observations and zebrafish treated with 2 showed higher Ru contents than those treated with 1. The distribution studies suggested that both complexes mainly accumulated in the intestines of the zebrafish.
Keywords: Cellular accumulation; Hydroxyquinoline; LA-ICP-MS; Pyridinecarbothioamide; Ru anticancer complexes; Zebrafish.
© 2023. The Author(s), under exclusive licence to Society for Biological Inorganic Chemistry (SBIC).
Similar articles
-
Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.J Biol Inorg Chem. 2012 Oct;17(7):1033-51. doi: 10.1007/s00775-012-0917-9. Epub 2012 Jul 12. J Biol Inorg Chem. 2012. PMID: 22791215
-
The aqueous stability and interactions of organoruthenium compounds with serum proteins, cell culture medium, and human serum.Metallomics. 2022 Jul 25;14(7):mfac043. doi: 10.1093/mtomcs/mfac043. Metallomics. 2022. PMID: 35751650 Free PMC article.
-
Dinuclear [{(p-cym)RuCl}2(μ-phpy)](PF6)2 and heterodinuclear [(ppy)2Ir(μ-phpy)Ru(p-cym)Cl](PF6)2 complexes: synthesis, structure and anticancer activity.Dalton Trans. 2014 Oct 21;43(39):14546-9. doi: 10.1039/c4dt01033g. Dalton Trans. 2014. PMID: 25160655
-
Recent developments in ruthenium anticancer drugs.Metallomics. 2009 Nov;1(6):458-70. doi: 10.1039/b904071d. Epub 2009 Aug 13. Metallomics. 2009. PMID: 21305154 Review.
-
Monomeric and dimeric coordinatively saturated and substitutionally inert Ru(ii) polypyridyl complexes as anticancer drug candidates.Chem Soc Rev. 2017 Nov 27;46(23):7317-7337. doi: 10.1039/c7cs00356k. Chem Soc Rev. 2017. PMID: 29027562 Review.
Cited by
-
The Chemistry of Anticancer Mononuclear and N-Bridged Dinuclear 8-Aminoquinoline Half-sandwich Metal Complexes.Chemistry. 2025 Apr 22;31(23):e202404366. doi: 10.1002/chem.202404366. Epub 2025 Mar 25. Chemistry. 2025. PMID: 40130746 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources